REMS
Risk Evaluation and Mitigation Strategy—an FDA safety program for particularly dangerous drugs requiring special warnings or limited distribution, sometimes abused to deny generics samples.
As defined in Robin Feldman on Drug Patents, Generics, and Drug Wars
Where it comes up · 2
- Robin Feldman on Drug Patents, Generics, and Drug Wars2 claims
- 377 - The Future Of Psychedelic Medicine 21 claim
Most important claims · 3 of 3Search all claims for “REMS” →
- Brand companies can block generics by refusing to sell them a sample needed to prove bioequivalence, restricting distribution to certain pharmacies or hospitals or invoking REMS safety protocols to claim the generic isn't a qualified buyer—and even when the FDA says transfer is fine, the brand can refuse, leaving the parties in a standoff that keeps the generic off the market.Robin Feldman on Drug Patents, Generics, and Drug Wars
- Martin Shkreli raised an off-patent drug from $13.50 to $750 a tablet and, although the drug had no REMS safety protocol, his company unilaterally declared it would distribute only through certain safety protocols and distributors—an FDA-unrequested move designed to deny generics a sample and create a competition-free zone, with an executive admitting they wouldn't make it easier for generics.Robin Feldman on Drug Patents, Generics, and Drug Wars
- The FDA can ask the sponsor, Lykos, to provide a Risk Evaluation and Mitigation Strategy (REMS) plan establishing guardrails around the advisory committee's concerns; this would enable regulatory approval of MDMA-assisted therapy while continuing to collect adverse-event and safety data in post-approval Phase 4 testing, which is especially valuable because administration will vary more widely once out of the strict Phase 3 protocol.377 - The Future Of Psychedelic Medicine 2